Ignite Creation Date:
2024-07-17 @ 11:10 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06467019
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-06-14
Brief Title:
Informative Exhibition for Deprescribing Benzodiazepines
Sponsor:
Consorci Sanitari de lAlt Penedès i Garraf
Organization:
Consorci Sanitari de lAlt Penedès i Garraf
Study Overview
Official Title:
Impact of an Interactive and Informative Exhibition on Benzodiazepine Use on Deprescription
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ESUB
Brief Summary:
The goal of this trial is to determine if an interactive and informative exhibition in the waiting room of a Primary Care Clinic can reduce the use of benzodiazepines in adults The main question it aims to answer is
Does an interactive and informative exhibition reduce the number of participants using benzodiazepines Researchers will compare benzodiazepine consumption before and after the interactive and informative exhibition implementation at study center
Participants will receive an informative and interactive exhibition on the risks of chronic benzodiazepine use A single informative session on the same topic will be conducted for health professionals
Does an interactive and informative exhibition reduce the number of participants using benzodiazepines Researchers will compare benzodiazepine consumption before and after the interactive and informative exhibition implementation at study center
Participants will receive an informative and interactive exhibition on the risks of chronic benzodiazepine use A single informative session on the same topic will be conducted for health professionals
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None